<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nine individuals between 15 and 43 years of age with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> underwent allogeneic marrow transplantation following <z:chebi fb="0" ids="28901">busulfan</z:chebi> 16 mg/kg and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg </plain></SENT>
<SENT sid="1" pm="."><plain>These individuals were not considered optimal candidates for autologous transplantation chiefly because of marrow involvement or resistance to chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted and eight achieved complete remission </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients relapsed; one patient died of transplant-related complications </plain></SENT>
<SENT sid="4" pm="."><plain>Five individuals are disease-free survivors between 103 and 1169 days following transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>Of three individuals with relapsed Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> none experienced a sustained disease-free interval following transplantation </plain></SENT>
<SENT sid="6" pm="."><plain>Three of four individuals with large cell or lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are surviving 585 to 1169 days following transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>Allogeneic marrow transplantation following <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> appears reasonably safe and is effective in selected patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who are not good candidates for autologous marrow transplantation </plain></SENT>
</text></document>